Fli1 and Tissue Fibrosis in Various Diseases.
Elena V MikhailovaIrina V RomanovaAlexei Y BagrovNatalia I AgalakovaPublished in: International journal of molecular sciences (2023)
Being initially described as a factor of virally-induced leukemias, Fli1 (Friend leukemia integration 1) has attracted considerable interest lately due to its role in both healthy physiology and a variety of pathological conditions. Over the past few years, Fli1 has been found to be one of the crucial regulators of normal hematopoiesis, vasculogenesis, and immune response. However, abnormal expression of Fli1 due to genetic predisposition, epigenetic reprogramming (modifications), or environmental factors is associated with a few diseases of different etiology. Fli1 hyperexpression leads to malignant transformation of cells and progression of cancers such as Ewing's sarcoma. Deficiency in Fli1 is implicated in the development of systemic sclerosis and hypertensive disorders, which are often accompanied by pronounced fibrosis in different organs. This review summarizes the initial findings and the most recent advances in defining the role of Fli1 in diseases of different origin with emphasis on its pro-fibrotic potential.
Keyphrases
- systemic sclerosis
- immune response
- interstitial lung disease
- induced apoptosis
- poor prognosis
- blood pressure
- acute myeloid leukemia
- dna methylation
- bone marrow
- rheumatoid arthritis
- transcription factor
- idiopathic pulmonary fibrosis
- dendritic cells
- inflammatory response
- cell death
- endoplasmic reticulum stress
- drug induced
- anti inflammatory
- cell cycle arrest
- replacement therapy